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license (http://creativerisk to develop Alzheimer’s disease (AD). Amyloid-b and tau pathology are omnipresent from age
40 years onward, but clinical symptoms do not appear in all DS individuals. Dementia diagnostics
is complex in this population, illustrating the great need for predictive biomarkers. Although blood
biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-b42,
high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and
are increasingly used in clinical practice. Surprisingly, CSF biomarkers have been barely evaluated
in DS. Breaking the taboo on CSF analyses would finally allow for the elucidation of its utility in (dif-
ferential) diagnoses and staging of disease severity. A sensitive and specific biomarker profile for AD
in DS would be of paramount importance to daily care, adaptive caregiving, and specific therapeutic
interventions.
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Alzheimer’s disease
Down syndrome (DS), present in nearly six million peo-
ple worldwide, is the main genetic cause of intellectual
disability in humans with a live birth prevalence of approx-
imately one in 650 to 1000 [1,2]. DS is caused by the
triplication of chromosome 21, hence trisomy 21. In
addition to the intellectual disability, people with DS face
an extremely high risk to develop dementia because of
Alzheimer’s disease (AD) later in life. By the age of 65,
68% to 80% of DS individuals develop AD [3] compared
with about 11% of those aged .65 years in the generaluthor. Tel.: 131-50-361-4650; Fax: 131-50-361-
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).(nonintellectually disabled) population [4]. Because of
improved medical care, DS life expectancy has increased
tremendously in the last century: from 9 years in 1929 to
an actual average life expectancy of 61.1 years for men
and 57.8 years for women [5]. Consequently, dementia has
become evident in the aging DS population, being a major
challenge in current daily care.
The high risk for AD in DS is generally attributed to the
triplication of the amyloid precursor protein (APP) gene,
encoded on chromosome 21. The APP protein is cleaved
by b- and g-secretase into amyloid-b (Ab) peptides, the
main constituent of the amyloid plaques found in AD. Over-
production of the APP protein, and thus increased formation
of its splicing product Ab, is present from birth onward, re-
sulting in early Ab accumulation and deposition in the brain
(Fig. 1). Plaque formation has been reported to start with
deposition of the longer Ab1–42 fragments, already
observed in a 12-year-old child with DS, later followed byimer’s Association. This is an open access article under the CC BY-NC-ND
Fig. 1. Schematic illustration of AD neuropathology and related changes in CSF biomarkers in DS. DS is caused by trisomy 21. The APP gene is encoded on
chromosome 21, causing an overproduction of the APP protein in DS from birth onward. The enzymes b- and g-secretase cleave the APP protein into Ab pep-
tides, which aggregate into plaques. The longer Ab1–42 fragments are most prone to aggregate. Extensive neuropathology, that is, extracellular plaques, but also
intracellular neurofibrillary tangles consisting of p-tau and t-tau, increases strongly in the third and fourth decade of life in virtually all DS individuals. These
neuropathologic hallmarks are reflected by altered levels of CSF biomarkers. The CSFAD profile (low levels of Ab42, and high levels of p-tau and t-tau) dem-
onstrates high sensitivity and specificity in the general population. Whether a similar biomarker profile is useful for AD in DS remains to be elucidated. The very
limited number of small-sized CSF studies in DS suggests that CSFAb1–42 increases in early childhood when the aggregation of Ab1–42 into plaques is still
relatively low. Once the deposition of Ab1–42 into plaques augments (i.e., reduced clearance from the brain), CSFAb1–42 gradually decreases. In contrast, CSF
t-tau and p-tau both correlate positively with age in DS. Abbreviations: Ab, amyloid-b; APP, amyloid precursor protein; CSF, cerebrospinal fluid; DS, Down
syndrome; p-tau, phosphorylated tau; t-tau, total tau.
A.D. Dekker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 1-102formation of more compacted fibrillary plaques that contain
Ab1–40 as well [6]. Neuropathologic studies showed that
the abundance of amyloid plaques and neurofibrillary tan-
gles—the second hallmark of AD pathology—increases
strongly in the third and fourth decade of life. By the age
of 40 years, pathology is omnipresent in virtually all persons
with DS, meeting the neuropathologic criteria for AD [7,8].
Interestingly, a 78-year-old DS woman with a partial trisomy
21 lacking the third copy of the APP gene was found to
display neither symptoms of dementia nor evident AD pa-
thology [9], illustrating the central role of the triplication
of the APP gene.
Strikingly, despite the presence of pathology from
midlife, not all DS individuals develop clinical dementia
symptoms, thus complicating the prediction and monitoring
of (the course to) dementia [10]. Indeed, DS individuals may
reach their 70s free of dementia symptoms [11]. Therefore,diagnosing AD in DS is relatively difficult compared
with the general population considering the (variable extent
of) intellectual disability, pre-existing behavior, and comor-
bidities that might be misinterpreted as dementia symptoms.
Differentiating among low(er) cognitive capacities because
of the intellectual disability, cognitive decline because of
normal aging, and deterioration because of AD is a fairly
complex endeavor, heavily relying on clinical observations
and caregiver reports [10,12].
Consequently, an objective biomarker profile for AD in
DS would greatly aid the diagnostic procedure and
contribute to more sensitive and earlier diagnoses. In fact,
predicting the onset and monitoring the progression of AD
in DS is of paramount importance to daily care. It would
contribute to awareness and understanding among care-
givers and relatives, leading to increased acceptance—the
starting point for adaptive caregiving: allocating additional
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agement and support. Furthermore, it would enable specific
therapeutic interventions. Currently, treatment options are
limited: in the few randomized controlled trials in the DS
population, effectiveness of donepezil and memantine was
not proven [13]. Alternatively, contemporary intellectual
disability care focuses on timely (non-)pharmacologic ther-
apy to reduce behavioral and psychological symptoms of de-
mentia—the major cause of referral [14]—to improve
quality of life and reduce caregiver burden [10,15].
Although the process of neurodegeneration cannot yet be
prevented or stopped, a recently completed clinical trial
(phase Ib) using immunotherapy with aducanumab
reported a dose- and time-dependent reduction of Ab pla-
ques in the brain of patients with prodromal or mild AD,
indicating the potential of this human monoclonal antibody
as disease-modifying strategy for AD [16].2. Cerebrospinal fluid biomarkers for AD in the general
population
In the general population, mounting evidence demon-
strates the high sensitivity and specificity of cerebrospinal
fluid (CSF) biomarkers for AD, contributing to accurate
and earlier diagnosis, and aiding the differential diagnosis
of AD from other dementia etiologies. Because CSF is in
direct contact with the extracellular space in the brain,
CSF biomarkers are considered to reflect biochemical
changes in the brain better than other biological fluids
such as plasma/serum or urine [17]. In recent years, a num-
ber of studies confirmed the diagnostic value of the so-called
“AD signature” or “AD profile” in CSF: low levels of Ab42
and high levels of total tau (t-tau) and phosphorylated tau at
threonine181 (p-tau) typically found in patients with
AD compared with cognitively normal control subjects, in-
dividuals with subjective memory complaints, and patients
with other non-AD dementias [18–23]. Low Ab1–42,
high t-tau, and high p-tau levels in CSF, respectively,
reflect the deposition of Ab1–42 into plaques, neuronal
damage and degeneration, and neocortical neurofibrillary
pathology [18].
As a consequence, this panel of CSF biomarkers receives
vast attention in research and in clinical practice. CSF bio-
markers have been included in the revised diagnostic criteria
for AD by the National Institute on Aging and the Alz-
heimer’s Association [24,25] and are increasingly used in
memory clinics [26]. Routine CSF analysis has been recom-
mended by the European Federation of Neurological Soci-
eties with respect to the differential diagnosis of atypical
AD [27]. In most of the European Federation of Neurolog-
ical Societies member countries Ab1–42, t-tau, and p-tau
are frequently evaluated, although specific cutoff values
for these three biomarkers may differ per country or per cen-
ter. Although the frequency of lumbar punctures was tradi-
tionally low in Canada and the United States in
comparison with northern European countries, clinicalresearch initiatives such as the Alzheimer’s Disease Neuro-
imaging Initiative positively impacted the attitude toward
lumbar punctures in recent years and contributed to the im-
plementation of CSF biomarkers in clinical practice [18].
Indeed, lumbar punctures, regularly offered to patients as
option in the standard clinical procedure, may aid neurolo-
gists in their diagnostic workup: CSF biomarkers were found
to change diagnoses, increase diagnostic confidence, and
affect patient management [28].
More recently, Skillb€ack et al. [20] demonstrated that low
Ab1–42, high t-tau, and high p-tau correlated with cognitive
decline in patients with AD represented by the Mini-Mental
State Examination scores, thus indicating that these CSF
biomarkers might be useful for staging of disease severity.
Given that AD neuropathology is omnipresent in DS brains
from the age of 40 years onward, but not all individuals
develop clinical dementia symptoms, it is of utmost impor-
tance to monitor clinical symptoms. Biomarkers that would
not only reflect the deposition of neuropathology but also
correlate with cognitive decline would be a major advantage.
After all, people cope with the symptoms rather than neuro-
pathology, that is, the presence of neuropathology without
clinical symptoms does not affect daily care.
Although the importance of CSF biomarkers in AD diag-
nosis has long been recognized in the general population and
efforts are made to standardize (pre-)analytical procedures
[18,29], CSF biomarkers for AD in DS have been largely
neglected so far. Despite their high risk on AD, not more
than a mere handful of small-sized studies evaluated
Ab42, t-tau, and p-tau in CSF of DS individuals. Key study
information and CSF results from the five published studies
are listed in Table 1.3. Few CSF studies in DS
To our knowledge, the first study measuring CSF levels of
Ab species was conducted by Tamaoka et al. in 1999 [30].
Ab1–40, Ab1–42, and the truncated species Abx–40 and
Abx–42 were measured in CSF of five DS individuals in
their 50s (55.3 6 3.4 years) and compared with 34 non-DS
patients (67.9 6 10.4 years) diagnosed with neurologic dis-
eases not associated with dementia (diseased control group).
Althoughmean CSF levels of Ab1–40 and the truncated spe-
cies did not significantly differ between both groups,
Ab1–42 was significantly lower in DS than in diseased con-
trol subjects, which corresponds to lower CSF Ab1–42 re-
ported in patients with AD in the general population.
Considering the mean age of the DS group, reduced
Ab1–42 likely reflects the deposition of AD pathology in
the DS brain that is omnipresent from the age of 40 years on-
ward. Whether DS individuals were clinically diagnosed
with dementia was not described [30].
Two years later, a Finnish group determined Ab1–42 and
t-tau in CSF of 12 DS individuals (including three subjects
with a clinical dementia diagnosis) and 19 non-DS, nonde-
mented control subjects [8]. CSF tau did not differ
Table 1
CSF levels of Ab1–42, t-tau, and p-tau in DS
Study
reference Study population
Clinical dementia
diagnosis CSF Ab1–42 (pg/mL) CSF t-tau (pg/mL)
CSF p-tau
(pg/mL)
[30]* 5 DS (55.3 6 3.4 y) Unknown 817y 6 496 — —
34 Diseased control subjects (67.9 6 10.4 y) No AD 1457y 6 745 — —
[8] 12 DS (41 6 11 y) 3 Clinical history
of dementia
572z 6 160
(,40 y, n 5 6)
370zx 6 105
(.40 y, n 5 6)
144{ 6 101
(,40 y, n 5 6)
500{ 6 341
(.40 y, n 5 6)
—
19 Control subjects (53 6 5 y) Nondemented 578x 6 129 246 6 109 —
[31] DS children, longitudinal: 8 mo (n 5 9),
20–40 mo (n 5 11), and 54 mo (n 5 4)
n/a 1200 (8 mo), 1800 (20–40 mo),
and 1800 (54 mo)
n.s. n.s.
[32] 12 DS (41 6 11 y) 3 Clinical history
of dementia
637 6 201 431 6 369 52 6 31
20 Healthy control subjects (40 6 15 y) n/a 674 6 145 210 6 87 34 6 8.8
[35] 12 DS (41 6 11 y) 3 Clinical history
of dementia
Relative abundance (HI-MS)
lowest in DS compared with
control subjectsjj
— —
20 Healthy control subjects (40 6 15 y) n/a — —
Abbreviations: AD, Alzheimer’s disease; Ab, amyloid-b; CSF, cerebrospinal fluid; DS, Down syndrome; HI-MS, hybrid immunoaffinity mass spectrometry;
n.s., not specified in the article; p-tau, phosphorylated tau; t-tau, total tau.
*CSFAb1–42 is expressed in picomolars in the original publication. Concentrations have been converted into picograms per milliliter using 4512.21 g/mol as
molecular mass of Ab1–42 in CSF [33].
yP , .05.
zP , .05.
xP , .01.
{P , .01.
jjP , .0001.
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was significantly lower in older DS individuals (aged
.40 years) compared with control subjects (P, .01). Apoli-
poprotein E genotypewas not related to eitherAb1–42 or tau.
To explore a possible age-related change in CSF values, the
authors recruited people in awide age range (21–61 years). In
the DS group, CSF Ab1–42 correlated negatively with age
(r520.785; P, .005), whereas t-tau demonstrated a posi-
tive age correlation (r 5 0.718; P , .05). Alternatively, the
DS study population was divided into a younger and older
age group with the age of 40 years as cutoff: CSF levels of
Ab1–42 and t-tau were, respectively, lower and higher in
older (.40 years, n 5 6) than in younger DS individuals
(,40 years, n 5 6). Interestingly, the highest level of CSF
Ab1–42 was found in the youngest participant with DS
(aged 21 years), leading the authors to suggest that CSF
Ab1–42 increases because of the trisomy 21–related over-
production of the APP protein, and thus of Ab fragments,
whereas the Ab accumulation into plaques is still low [8,34].
Increased CSFAb in young DS individuals is further sup-
ported by findings of Englund et al. [31]. They measured a
series of Ab species (Ab1–37, Ab1–38, Ab1–39, Ab1–40,
and Ab1–42) and t-tau and p-tau in longitudinal CSF sam-
ples from a small group of very young DS children at
8 months (n5 9), 20 to 40 months (n5 11), and 54 months
(n5 4). Indeed, increasing levels of all Ab species (Western
blot) were observed from age 8 to 54 months, although onlyAb1–37 and Ab1–38 reached significance. The ratio
Ab1–42/Ab1–40 did not change over time. CSF t-tau and
p-tau levels did not change significantly over the months,
which would correspond to the likely absence of tau pathol-
ogy at this young age.
Recently, Portelius et al. [32] retested the Finnish CSF
aliquots [8] (n 5 12 DS) to determine whether the
aforementioned results could be replicated. In this new
study, other Ab species (Abx–38, Abx–40, and Abx–42)
and soluble APP fragments (sAPPa and sAPPb) were
measured in addition to Ab1–42, t-tau, and p-tau. Compared
with a healthy age- and gender-matched control group
(n 5 20), CSF levels of Abx–40, sAPPa, and sAPPb were
significantly higher in DS. Abx–38, Abx–42, Ab1–42,
t-tau, and p-tau did not differ significantly between both
groups. Resembling the previous study, a negative correla-
tion was observed between the Ab1–42 concentration and
age (r 5 20.69, P 5 .015). T-tau was positively correlated
with age (r 5 0.76, P 5 .0062). No correlations with age
were found for the other measured markers. Subsequently,
the DS group was divided again into a younger
(,40 years, n 5 6 DS) and an older subgroup (.40 years,
n 5 6 DS), revealing that older DS individuals had signifi-
cantly higher t-tau and p-tau concentrations than their
younger counterparts. Lower Ab1–42 levels in the older
DS group, as reported in the first study of this cohort [8],
could not be replicated here [32].
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by performing hybrid immunoaffinity enrichment of the CSF
Ab peptides followed by matrix-assisted laser desorption/
ionization time-of-flight/time-of-flight (MALDI-TOF/TOF)
mass spectrometry, demonstrating that the relative abundance
of Ab1–42 was significantly decreased in DS (n 5 12)
compared with control subjects (n 5 20, age- and gender-
matched). This relative abundance is based on the relative
peak heights/areas of the various CSF Ab peptides and there-
fore does not directly reflect the absolute abundance, but rather
indicates relative changes in the peptides. Relative Ab1–42
levels were also found to correlate negatively with age in DS
[35], which resembles previous (absolute) findings [8,32] and
likely relates to the increased deposition into plaques/reduced
clearance.
In summary, the previously described studies suggest that
CSF Ab1–42 levels are lower in DS than in non-DS control
subjects and correlate negatively with age in the DS popula-
tion. In early childhood, Ab levels tend to increase in DS,
followed by a gradual decrease (reduced clearance from
the brain) once the deposition of Ab1–42 into plaques aug-
ments. Tau, on the other hand, does not differ between DS
and control subjects but appears to correlate positively
with age in DS individuals (schematically illustrated in
Fig. 1). The aforementioned results should be interpreted
with caution, however, given the very small study sizes
(not exceeding 12 DS participants, thus being hugely under-
powered), groups that were not age-matched, and the fact
that three of five studies analyzed CSF from the same partic-
ipants [8,32,35]. Importantly, clinical diagnoses and the
severity of dementia were not taken into account, leaving
the question open whether these biomarkers would only
reflect neuropathology or correlate with disease status and
severity as well. Although it was originally thought that
CSF biomarkers were not useful for staging of disease
severity [18], low Ab1–42, high t-tau, and high p-tau were
recently found to correlate with the Mini-Mental State Ex-
amination scores, that is, disease severity, in the general pop-
ulation [20]. Therefore, future DS biomarker studies need
high-quality clinical documentation with standardized and
validated cognitive, behavioral, and functional testing to
establish whether CSF biomarkers in DS correlate with dis-
ease severity and progression as well.4. Need for CSF analyses in DS
The importance of research on AD in DS and the true
need for biomarkers reflecting clinical symptoms are now
justly recognized in the field [1,3,36]. Indeed, various
international working groups on AD in DS have been
established in recent years, such as the Committee for
Clinical Research of the Trisomy 21 Research Society, the
Professional Interest Area on Down Syndrome and
Alzheimer’s Disease by the American Alzheimer’s
Association, and the Down Syndrome and Other Genetic
Developmental Disorders Network initiated by theEuropean College of Neuropsychopharmacology. Despite
all efforts, CSF analyses evidently remain a problematic
avenue.
The question arises what hampers the implementation of
CSF biomarkers in DS. First of all, one could argue that an
etiologic diagnosis of dementia is of limited added value
in DS considering their evident genetic predisposition to de-
mentia of the Alzheimer type. Such a view, however, ignores
the complex nature of dementia diagnostics in this popula-
tion. Disentangling dementia from normal aging and
distinguishing dementia from depression—a particular
vulnerability in DS—are major challenges for clinicians.
Symptoms of depression and dementia overlap considerably
and may occur concomitantly [10,37]. In particular,
depressive symptoms can mimic dementia by negatively
affecting cognition and daily functioning. Misdiagnosis of
depression as dementia, or vice versa, may strongly impact
the selected therapeutic strategy. An established and
validated CSF AD biomarker profile in DS would enhance
sensitivity and specificity of diagnosis of AD in DS, that
is, to confirm the AD diagnosis. Furthermore, CSF
biomarkers might identify those individuals at risk for
conversion to clinical AD, which would strongly aid
adaptive caregiving.
Moreover, lumbar punctures are regarded a relatively
invasive procedure, raising ethical issues especially in this
vulnerable intellectually disabled population. It has been re-
ported that patients in the general population may fear
adverse effects and pain, whereas clinicians may have a
negative attitude toward lumbar punctures with respect to
time constraints and lack of training [18]. The most common
complication concerns the postlumbar puncture headache
(PLPH). Although the incidence of PLPH differs markedly
per site and procedure [26], the frequency and severity of
PLPH has been reported low in demented patients [38].
The use of an atraumatic needle, for instance, is associated
with a lower incidence of PLPH and a favorable safety pro-
file in patients with AD [39,40]. Interestingly, Peskind et al.
reported ,2% PLPH [39], which approaches the risk of
headache related to positron emission tomography (PET)
imaging of amyloid deposition (1.8%) [18], a technique
that has become popular in DS research. In that respect, lum-
bar punctures convey a relatively low risk on complications,
also shown by the increasing popularity of CSF biomarker
analyses in memory clinics throughout the world [26].
With respect to DS, the implementation of CSF sampling
is further complicated by the fact that most DS individuals
are not capable of weighing the benefits and risks and
make a deliberated decision about consent and participation.
Consequently, one relies on informed consent by proxy from
the legal representative, often the parents. Although a sub-
stantial body of evidence points at the relatively low risk
on complications, good safety profile and high sensitivity
and specificity of the CSFAD profile in the general popula-
tion, such data are not broadly available for DS. More
recently, we have shown the safety of lumbar punctures in
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sampling, the Down Alzheimer Barcelona Neuroimaging
Initiative (DABNI), using a validated protocol with a semi-
structured telephone interview [41]. Among the participants,
90% did not report any complication. Headache (6.25%) was
found to be the most frequent complication, with only one
participant suffering from a typical PLPH with moderate
severity. The incidence of reported complications was found
to be lower than in the general population. Given the rela-
tively early onset of AD in DS, it is of interest to mention
that younger age and female gender appear as risk factors
for PLPH in the general population [26]. Unfortunately,
the aforementioned safety study in DS was not powered to
assess this [41], nor were these risk factors addressed in
the few CSF studies in DS so far [8,30–32,35]. Therefore,
balancing the pros and cons in the context of DS is more
complicated and will be highly individual. In addition to
the personal decision on whether to participate, approval
of the Institutional Review Board might be a substantial
hurdle. From the American perspective, Hartley et al. state
that DS individuals form “a health disparity population”
with an extremely high risk for AD who “should have
access to the latest interventions and clinical trials,” a
strategical argument that would contribute to approval by
the Institutional Review Board [36].
Many researchers have circumvented this issue in
advance by designing studies with less invasive procedures,
mainly collection of plasma/serum. Because blood examina-
tion is part of routine clinical workup, including tests for hy-
pothyroidism and vitamin B12 deficiency with respect to the
dementia diagnosis in DS, drawing additional plasma/serum
for research purposes has been widely accepted. For
instance, several DS studies have analyzed Ab1–42 and
Ab1–40 in serum or plasma in relation to the status of de-
mentia. Results summarized in Coppus et al. [42] have not
been concordant, however. Notably, it remains indistinct
whether plasma/serum Ab1–42 reflects pathologic changes
in the brain, as peripheral cells may also produce Ab. In
the general population, plasma Ab1–42 correlated neither
with CSF Ab1–42 nor with amyloid burden in frontal and
temporal neocortex [43,44].
Accordingly, CSF is the preferred source of AD bio-
markers: it is in direct contact with the extracellular space,
and confounding influences from the periphery are dimin-
ished. It has been argued that lumbar punctures might be
difficult in DS because they may not directly benefit the in-
dividual [36]. However, this runs the risk of circular
reasoning: if the aforementioned CSF AD profile estab-
lished in the general population is not thoroughly validated
in DS, evaluation of CSF Ab1–42, t-tau, and p-tau will not
benefit the diagnostic process in DS. An apparent discrep-
ancy exists between large CSF biomarker studies in the gen-
eral population and (very) small CSF studies in DS. Clearly,
different standards are applied in the general population
compared with people with intellectual disabilities, as
shown by the fact that DS studies with only 12 individualshave still been accepted for publication in recent years. On
the basis of the very few available studies and regular dis-
cussions with colleagues in the field, a kind of taboo
emerges on lumbar punctures in DS. Despite a broad
consensus on the need to perform CSF studies in DS [36],
CSF sampling has been hardly incorporated in study proto-
cols so far.
For instance, consideration of ongoing larger scale clin-
ical initiatives confirms the limited focus on CSF biomarkers
in DS adults. In the ClinicalTrials.gov registry, a search for
“Down syndrome 1 CSF” or “Trisomy 21 1 CSF” yielded
only two results: a phase I dose escalation study of the
ACI-24 liposome vaccine (developed to evoke an antibody
response against aggregated Ab peptides) in 24 DS individ-
uals (aged 35–45 years) mentioning “change from baseline
over 25 months in plasma/CSF amyloid [and] tau” as a sec-
ondary outcome measure [45], and the start of a new bio-
bank, planning to include CSF sampling as well [46].
Moreover, the Down Syndrome Biomarker Initiative, one
of the major DS initiatives in the United States, primarily fo-
cuses on neuroimaging and does not mention CSF bio-
markers in their pilot study publication [47]. Indeed,
amyloid PET receives substantial attention in DS. PET neu-
roimaging, however, is not likely to replace CSF AD bio-
markers: a recent study in the general population revealed
that CSF Ab1–42 becomes abnormal before amyloid PET,
that is, abnormal Ab accumulation is detected earlier
through CSF analysis [48]. Clearly, CSF analyses in DS
remain marginally available and lumbar punctures are far
from being a common procedure.
In the general population, however, CSF biomarkers are
increasingly being included in clinical trials of disease-
modifying therapies for AD. The use of CSF biomarkers
in clinical trials serves different purposes—reviewed in
[49]: (1) to evaluate and quantify the pharmacodynamic ef-
fects of AD-modifying therapies, for example, CSFAb1–42
levels as an indicator of the effect of a new b-secretase
inhibitor, (2) to contribute to a more homogenous and accu-
rate selection of patients (aiding the clinical diagnosis on
which patient enrollment is generally based), and (3) to iden-
tify prodromal subjects or those at risk to convert to AD.
Moreover, CSF biomarkers might serve as surrogate end
points of disease progression [49]. Importantly, clinical trials
for preventive or curative treatment of AD in DS are war-
ranted. Because the diagnosis of dementia and the clinical
evaluation of disease progression in this high-risk population
are rather complex, the availability of valid CSF biomarkers
would be crucial in such trials.
Are researchers limiting themselves in advance by not
including CSF measures in study protocols, afraid of long
delays in Institutional Review Board procedures or negative
responses from families? Taking the extremely high risk for
AD into account, the authors are convinced that people with
DS should get the same opportunities and high-quality
research as patients with AD in the general population.
Rather than deciding for DS individuals and their caregivers
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apply a “you never know, until you ask” approach. In our
experience, caregivers and relatives are very open to scienti-
fic research and willing to consider participation requests as
long as the information is crystal clear and the procedure is
adapted to people with DSwith staff that is familiar with DS-
specific circumstances. Indeed, the CSF studies described
previously (listed in Table 1) and three other studies
measuring concentrations of monoamine neurotransmitters
and metabolites [50,51], and proteins [52], demonstrate
that lumbar punctures in DS are within the bounds of possi-
bility. The CSF production rate and the caudorostral gradi-
ents of total CSF protein have been reported normal in DS
compared with age-matched non-DS healthy control sub-
jects [53], thus not constituting any medical barrier herein.
Importantly, within the DABNI study—currently the only
DS cohort study in Europe to offer CSF sampling on a large
scale—more than 20% of DS individuals and their families
consented to a lumbar puncture [41,54], which is a
substantial proportion given the aforementioned ethical
considerations. To the best of our knowledge, no studies so
far have further assessed the reasons to refuse a lumbar
puncture in DS. In our clinical experience, however, these
reasons do not differ from the general population (i.e.,
protection of the individual, fear of adverse effects and
pain, and a lack of interest in the etiologic diagnosis),
although informed consent by proxy is a complicating
factor. Evidently, not all eligible individuals will
participate in such studies, but in multicenter approach
sufficiently large numbers are feasible.5. Future avenues
CSF biomarker studies in DS are still in its infancy, but
the results on the feasibility, safety, and acceptance of lum-
bar punctures are promising. Accordingly, which approach
should be considered to move the field further? First, most
studies in general population have been performed within
the setting of specialized memory clinics in which patient
care and research converge, whereas only a very few clinics
have specialized in DS. Reinforcing this infrastructure for
DS by fostering collaboration between memory clinics and
intellectual disability experts is warranted, for example,
the DABNI study has proven the success of such a partner-
ship [41]. Nevertheless, not all individuals will undergo a
lumbar puncture, pointing at the need for a multicenter
approach to achieve sufficiently large and relevant sample
sizes. Together with the key DS clinical research centers in
Europe we are working on harmonizing clinical protocols
and have initiated the first steps toward an European collab-
orative biobanking initiative for DS, resembling the concept
of the renowned Dutch Parelsnoer Institute for Neurodegen-
erative Diseases—a prospective, standardized, multicenter
cohort study strongly focusing on biomarkers for early and
differential diagnosis of dementia and disease monitoring
in the general population [55].Consequently, this would allow to determine the diag-
nostic value of the CSF AD profile (low Ab42, high t-tau,
and high p-tau) and investigate alternative CSF biomarkers
for AD in DS. Candidate biomarkers have been primarily
identified in blood so far, such as the major (nor)adrenergic
metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG).
Compared with DS individuals without dementia, MHPG
levels in serum were found to be significantly lower in
demented persons with DS (P, .0001) but also in the nonde-
mented individuals who converted to dementia during clinical
follow-up (P, .0001), pointing at the predictive potential of
MHPG [56]. Measuring MHPG in CSF would be the logical
next step, particularly after the combination of CSF MHPG
with CSF Ab42, t-tau, and p-tau was found to improve the
discrimination of AD versus dementia with Lewy bodies in
the general population [57]. Next to amyloid and tau
pathology, AD in DS is characterized by neuroinflammation
[58]. Portelius et al. [32] measured the microglial activation
marker YKL-40 and showed that DS subjects aged
.40 years (n 5 6) had significantly higher levels of
YKL-40 in CSF compared with their younger counterparts
(,40 years, n5 6). Whether YKL-40 or other inflammatory
markers would serve useful as biomarker remains to be eluci-
dated. Plasma/serum studies determining different proinflam-
matory factors in DS have not been decisive yet [59,60].
Finally, chromosome 21-encoded proteins that relate to AD
pathology—summarized in Wiseman et al. [3]—should be
studied more extensively in the context of biomarker identifi-
cation, such as the DYRK1A kinase [61,62] and the
synapse-associated protein synaptojanin-1 [63].6. Conclusions
The discrepancy between the presence of extensive AD
neuropathology from the age of 40 years and the highly var-
iable onset of clinical dementia symptoms in DS illustrates
the need for objective AD biomarkers in this population.
CSF Ab42, t-tau, and p-tau, contributing to the so-called
CSFAD profile, have proven useful in aiding AD diagnoses
in the general population and demonstrated high sensitivity
and specificity, and good safety profiles. Surprisingly, lum-
bar punctures are rarely performed in DS, a population at
high risk to develop AD dementia. As little as five studies
evaluated CSF Ab42, t-tau, and p-tau in DS. Being under-
powered and without considering the clinical status of de-
mentia, these studies, nonetheless, indicate that CSF
Ab1–42 negatively correlates with age and is lower than in
non-DS control subjects, whereas tau in DS correlates posi-
tively with age but does not differ between DS and control
subjects. Breaking the taboo on lumbar punctures in DS
would finally enable the scientific community to investigate
the utility of CSFAb42, t-tau, and p-tau in diagnosing AD in
DS, and if so, to what extent this panel of biomarkers would
aid differential diagnosis and staging of disease severity.
Because blood biomarkers have not yet proven useful in
clinical practice, a validated, sensitive and specific CSF
A.D. Dekker et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 1-108“AD in DS profile” would be of paramount importance to
daily care. It would contribute to understanding and accep-
tance among caregivers and relatives, enable adaptive care-
giving, allow for specific therapeutic interventions, and
might serve useful in future clinical trials for preventive or
curative treatment of AD in DS.
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to disclose.RESEARCH IN CONTEXT
1. Systematic review: Because of the limited number of
cerebrospinal fluid (CSF) studies in Down syndrome
(DS), we conducted a broad, unrestricted search
strategy to identify all relevant articles. Non-
English articles were not considered.
2. Interpretation: Amyloid-b42, total tau, and phos-
phorylated tau in CSF may strongly aid the diagnosis
of Alzheimer’s disease (AD) in the general popula-
tion. DS individuals are at very high risk to develop
AD and the diagnostic procedure in this population
is complicated by the pre-existing intellectual
disability and behavior. Because blood biomarkers
have not proven useful in clinical practice, it is sur-
prising that the large potential of CSFAD biomarkers
is barely studied in DS.
3. Future directions: Investigate the utility of CSF am-
yloid-b42, total tau, and phosphorylated tau, as
well as potential alternative CSF biomarkers in DS.
A sensitive and specific CSF biomarker profile for
AD in DS would allow for earlier and more accurate
diagnoses, aiding daily care and therapy.References
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